year-old man with nonobstructive hypertrophic cardiomyopathy (HCM). At 35 years of age, his brother (aged 39) died suddenly with a new diagnosis of HCM made at autopsy. A diagnostic evaluation ensued, and nonobstructive HCM was identified with a ventricular septal thickness of 31 mm. Because of the family history of sudden death (and his marked hypertrophy), an implantable cardioverter-defibrillator (ICD) was implanted for primary prevention of sudden death. Five years later, during sleep (1:00 AM), the ICD aborted an episode of ventricular fibrillation (VF) and restored sinus rhythm (Figure 1 ). Nine years passed without incident, and at 50 years of age, an identical VF event occurred during sleep, similarly terminated by a defibrillation shock. Now, at 56 years of age, the patient continues to be asymptomatic and active. His clinical course with HCM has been punctuated only by these 2 unpredictable sudden-death events effectively treated by an ICD prophylactically implanted for high-risk status.
Case 2: The patient is a 53-year-old female elementary school teacher with obstructive HCM. She presented at 44 years of age, asymptomatic, but with a strong family history of sudden deaths due to HCM in 2 brothers (aged 20 and 34 years, respectively). An ICD was implanted prophylactically, and 2 years later (at 46 years of age), VF was defibrillated during sleep. Over the next 6 years, 4 more appropriate interventions for ventricular tachycardia (VT)/VF followed.
Ventricular septal thickness is 21 mm; left ventricular outflow obstruction is absent at rest, although provoked with exercise (gradient, 70 mm Hg). By 51 years of age, exertional dyspnea and functional limitation had progressed despite maximum medical management, with the patient disabled in New York Heart Association functional class III. Surgical septal myectomy abolished both the outflow gradient and the patient's heart failure-related symptoms. Once again, at 53 years of age, she is asymptomatic and active, having experienced 2 adverse disease pathways, ie, sudden-death risk, and heart failure due to outflow tract obstruction, both of which were amenable to effective treatment strategies.
Introduction
Cardiovascular medicine advances rapidly, sometimes with blinding speed, to create new and important treatment initiatives. Coronary artery disease is at the core of cardiovascular practice, arguably an epidemic in this and much of the last century. But what of less common inherited heart diseases, historically overlooked, and sometimes seemingly lost among the vast number of patients with ischemic heart disease?
HCM is perhaps the most prominent among the genetic heart diseases. 2, 3 This is the story of how this condition, once regarded as rare and odd, but interesting (with grim prognosis) has come to be recognized as a relatively common, contemporary, and treatable clinical entity with established consensus recommendations and guidelines (Figures 1  through 3 ). 4 -7 This evolution represents an instructive message for the practicing community, and for their patients with HCM.
Historical HCM
HCM is now recognized as the most common cause of sudden cardiac death in the young (including trained ath-letes), present in at least 1 of 500 people in the general population, and probably affecting as many as 750 000 Americans. 8 However, to arrive at its current maturity, HCM has experienced a sometimes rocky and unpredictable course through its first 50 years. 9, 10 That journey has been punctuated by a myriad of obstacles, including periodic misunderstanding and contentious debate, and an often confusing and conflicted literature. Early, but now obsolete, discourse even suggested that HCM was not a distinct disease entity, or that true mechanical obstruction to left ventricular outflow did not exist. 9,10 A confusing litany of names (nϭ75) dominated the literature to describe the same condition, eg, among those idiopathic hypertrophic subaortic stenosis and hypertrophic obstructive cardiomyopathy now replaced by one, ie, HCM. 11 The early years of HCM (1960 -1965) were characterized by astute and novel clinical descriptions of a previously unrecognized clinical entity, first largely at the National Institutes of Health Clinical Center. Initially, there was a notable paucity of treatment options available. 2 Indeed, one of the first published articles on this disease from National Institutes of Health describing dynamic left ventricular outflow tract obstruction could only view treatment strategies in futile terms 12 : "At this time, we are aware of no method of management that can specifically and favorably influence the course of a patient with idiopathic ventricular hypertrophy."
Although this was an accurate assessment at that time (ie, 1959) ␤-blockers 13, 14 and surgical myectomy 15 were soon introduced. However, the cardiology community was slow to accept invasive treatment for HCM. For example, after an early but brief experience, myectomy was abandoned in the United Kingdom for 30 years.
An unfortunate notion took hold, which surprisingly persists with some frequency today, ie, the myth that HCM is an unrelenting disease without definitive or effective treatment options. HCM acquired the stigma of a disease characterized by an unpredictable downhill course affecting most patients. Perhaps contributing to this misconception now are the highly publicized but very uncommon athletic field deaths due to HCM in young previously undiagnosed sports participants. 16 Diseases such as HCM are susceptible to misunderstanding. Old concepts penetrate the consciousness and become entrenched, seemingly difficult to revise despite evidence to the contrary. Relatively uncommon conditions in clinical practice, such as HCM, represent challenges to individual cardiologists in order to best serve their patients by acquiring sufficient experience and exposure to fully appreciate nuances of the broad disease spectrum and its management.
Contemporary HCM
The clinical profile and treatment armamentarium of HCM has undergone a vast transformation. First, we now recognize that most genetically affected individuals are probably not identified clinically, including many who achieve normal life expectancy into their 70s, 80s, and even 90s, without disability or the necessity for major management interventions. 4 -7,17 Indeed, largely because of a generally heightened suspicion of the disease due in part to dissemination of advanced imaging modalities, asymptomatic HCM patients are fortuitously identified more frequently at relatively advanced ages.
In addition, risk for HCM-related complications (including sudden death) is paradoxically low in older patients after 60 years of age. 18 However, even now most recently diagnosed HCM patients seem surprised (and reassured) to learn this important principle about aging in HCM, having received a generally unfavorable message about their disease.
On the other hand, many patients who present to hospitals and clinics experience (or are at risk for) HCM-related complications 1,4 -7,19 -21 (Figure 3 ). The clinical course may progress along Ն1 adverse disease pathways, often drawing on treatment options designed for patients with other cardiac diseases ( Figure  3 ). Specific management strategies are dictated by these pathways; in principle, 
Prevention of Sudden Death
Sudden death is the most visible and devastating consequence of HCM, recognized since the initial pathological description in 1958. 3 However, prevention of sudden death is now a realistic aspiration for young patients with HCM. 1, 21 Although the history of HCM is encumbered by sudden death in young patients in the absence of therapy capable of averting that risk, systematic strategy has evolved in the past decade to protect such patients with ICDs. 1, 21 By virtue of automatically sensing and terminating VT/VF, the ICD is the only available treatment option capable of definitively prolonging life in HCM, thereby altering the natural history of the disease for many patients (Figure 1 ). The ICD in HCM registry, comprising high-risk patients, reports a primary prevention intervention rate of 4%/year, similar in adults and in children. 1 Although the ICD is a proven life-saving measure in HCM, the challenge remains to select more precisely those patients who will benefit from this therapy, including the small but important subset in which conventional risk markers are not predictive, but in whom sudden-death events may nevertheless occur. 21 Therefore, identifying more at-risk patients with novel markers continues to be an important goal for which contrast-cardiovascular MRI with extensive late-gadolinium enhancement (presumably myocardial scarring) shows significant promise. 22
Reversal of Heart Failure
In HCM, severe heart failure and exertional disability due to left ventricular outflow obstruction are potentially reversible 20 (Figure 2) . Surgical septal myectomy, pioneered by Andrew Morrow at National Institutes of Health 23 (and also advanced by others including Bill Williams in Toronto, John Kirklin and now Joseph Dearani, both of Mayo Clinic), has evolved to a safe procedure, effective in restoring full quality of life by normalizing left ventricular pressures.
Initially, myectomy, even in the most experienced hands, was encumbered by a 5% to 8% operative mortality, which undoubtedly tempered enthusiasm for this surgery. Consequently, the number of myectomy operations remained relatively small.
Only during the past 10 to 15 years has the frequency and importance of obstruction within the clinical spectrum of HCM been fully recognized 19, 24 (Figure 2) . Surgical septal myectomy has become an attractive and accessible option, evident by the dramatic increase in the number of operations performed annually at major centers. 25, 26 This renewed interest in myectomy is attributable to a strikingly low operative mortality of Յ1% due to contemporary myocardial preservation techniques, and increased surgical experience and innovation. 25, 26 For example, development of the extended myectomy approach recognizes the important contribution of submitral structures to left ventricular outflow tract obstruction. 4 -7,27 Notably, in addition to relief of outflow obstruction with enhanced quality of life, the myectomy operation also extends longevity with survival similar to that expected in the general population, and exceeding that of nonoperated symptomatic patients with obstructive HCM 20 (Figure 2) .
A percutaneous interventional strategy, ie, alcohol septal ablation, provides an important alternative to my- 19 Bottom, Surgical septal myectomy with abolition of LV outflow gradient is associated with long-term survival similar to that expected in the general US population, and exceeding that in symptomatic but nonoperated patients with obstructive HCM. Reproduced from Ommen et al, 20 with permission from the publisher. Copyright © 2005, New England Journal of Medicine. ectomy, [5] [6] [7] 28 selectively for those patients who are older and/or judged suboptimal surgical candidates because of comorbidity, or a strong personal aversion to surgery. 4 -7 Although alcohol ablation has proved effective in reducing outflow gradient and symptoms, it produces a potentially arrhythmogenic alcoholinduced transmural myocardial infarction, and in this respect differs significantly from myectomy. Nevertheless, the exuberance with which alcohol ablation has been embraced by the interventional cardiology community has stimulated visibility for HCM in general, and paradoxically has increased the focus on relieving outflow obstruction with myectomy. 25, 26, 28, 29 Rare patients who experience particularly advanced drug refractory and irreversible heart failure usually associated with systolic dysfunction and adverse left ventricular remodeling, due to microvascular ischemia and diffuse scarring (the end-stage phase), are candidates for heart transplantation as the only definitive treatment option. 30 Posttransplant survival in HCM patients is equivalent to that of other heart diseases, 85% at 1 year, 75% at 5 years, and 61% at 10 years, in comparison with 82%, 70%, and 49%, respectively, in non-HCM transplant recipients. 31
Atrial Fibrillation and Stroke
Atrial fibrillation (AF) is the most common sustained arrhythmia in HCM, occurring in Ϸ20% of patients (4-fold that of the general population). 32 In some patients, AF can be linked to progressive heart failure, and embolic stroke (although not to risk for sudden unexpected death). Management strategies for AF in HCM are similar to those for non-HCM patients and have similar efficacy. Standard pharmacological agents are administered aggressively to decrease the frequency of paroxysmal episodes, maintain sinus rhythm, control ventricular rate, and prevent embolic stroke with prophylactic anticoagulation. Selected patients with refractory AF are eligible for radiofrequency catheter ablation to obliterate the AF focus, a procedure that. at this early juncture, appears successful in restoring sinus rhythm and improving symptomatic status in the short term in Ͼ50% of patients. 33
Conclusions and Perspectives
HCM has emerged from an era of substantial misunderstanding, stigma, and pessimism to become a contemporary cardiovascular disease in which each of its adverse disease pathways and complications are associated with widely available and effective management strategies. These major therapeutic interventions available to HCM patients are capable of changing the natural history of the disease, including the prevention of sudden cardiac death (with the ICD) and reversal of heart failure with restored quality of life and extended longevity (with surgical myectomy).
Notably, the mature HCM management strategies addressed here are directly attributable to purely clinical principles and research, and are independent of the notable advances in molecular biology. The latter have defined the gene mutations encoding sarcomeric proteins that cause HCM, with the clinical impact largely confined to family screening, 34 but so far have assumed little role in the treatment and prognostic assessment of clinically expressed HCM.
Much work remains for this complex genetic disease, particularly in the area of risk stratification. Nevertheless, the ultimate objective of providing HCM patients with the opportunity to achieve normal life expectancy with good quality of life has become a realistic aspiration through the important contributions of many clinical practitioners and investigators since the infancy of this disease Ͼ5 decades ago.
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